During the fourth quarter of fiscal 2009 and first quarter of 2010, Salt Lake City-based molecular diagnostic testing firm Myriad Genetics expanded its ob-gyn sales staff by 50, for a total team of 300. There are now 150 sales reps based in oncology and 150 sales reps in women’s health. Going into their 2010 fiscal year, the company is also getting aggressive about its direct-to-consumer (DTC) marketing campaigns, announced company executives in a recent fourth-quarter earnings call. The Midwest campaign was launched on Aug. 17—three weeks earlier than originally planed. In addition, a DTC campaign in the southern states was reinitiated in mid-August. One hundred and thirty physicians have also been added to Myriad’s speaking panel to help market tests like the BRACanalysis, which helps to assess risk for developing breast or ovarian cancer.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

October 2009 - Table of Contents

LIR October 2009 (full PDF issue)

G-2 Reports’ Web-Based Connectivity Survey Finds 59% of Labs Connected to Physician EMR; Many Report Expected ROI in Less than 5 Years

Industry Exhales: $750 Million Tax Levy Dropped From Senate Finance Bill

Sonic Healthcare’s 2009 Revenues Up 27% to $2.5 Billion as Acquisition War Chest Grows to $644 Million

Genoptix, Myriad Genetics Continue to Lead in G-2’s Second-Quarter Benchmarking Analysis

Inside the Lab Industry: Many Labs Expect Five-Year Return on Investment in Web-Based Connectivity Systems Through New Clients, Expanded Business

Bostwick Labs Expands Mid-Atlantic Footprint with Launch of American International Pathology Laboratories

Lab Index Finishes the Summer Strong; Up 18% Over 13 Weeks, 42% for Full Year 2009

Industry Buzz: Myriad Genetics Expands Salesforce by 50 Reps to Aggressively Target Ob-Gyn Market